Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 8/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 7/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 7/20 | 0.47 |
| ▸ | CHRNB1 | P11230 | 3/20 | 0.47 |
| ▸ | CHRNB3 | Q05901 | 3/20 | 0.47 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.38 |
| ▸ | UGCG | Q16739 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5117175 | 0.98 | CHRNB2 (0.49) | CHRNB2CHRNB4CHRNA3CHRNB1CHRNB3 | |
| SCHEMBL5110035 | 0.91 | CHRNB2 (0.47) | CHRNB2CHRNB4CHRNA3CHRNB1CHRNB3 | |
| SCHEMBL5114726 | 0.88 | CHRNB2 (0.44) | CHRNB2CHRNB4CHRNA3CHRNB1CHRNB3 | |
| SCHEMBL5114127 | 0.88 | CHRNB4 (0.44) | CHRNB2CHRNB4CHRNA3CHRNB1CHRNB3 | |
| SCHEMBL5110310 | 0.88 | CHRNB2 (0.48) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL5114425 | 0.88 | CYP11B1 (0.41) | CHRNB2CHRNB4CHRNA3CHRNB1CHRNB3 | |
| Hydrochloric Acid SCHEMBL5121768 | 0.87 | CHRNB2 (0.43) | CHRNB2CHRNB4CHRNA3CHRNB1CHRNB3 | |
| SCHEMBL5107938 | 0.86 | CHRNB4 (0.47) | CHRNB2CHRNB4CHRNA3CHRNB1CHRNB3 | |
| SCHEMBL5112358 | 0.86 | CHRNB4 (0.46) | CHRNB2CHRNB4CHRNA3CHRNB1CHRNB3 | |
| SCHEMBL5120666 | 0.85 | CHRNB2 (0.50) | CHRNB2CHRNB4CHRNA3CHRNB1CHRNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1551843-A1 | DIAZABICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CNS AND OTHER DISORDERS | Pfizer Products Inc. (US) | 2005-07-13 | — | — | EP | claimed |
| US-20040106603-A1 | Diazabicyclic compounds useful in the treatment of CNS and other disorders | PFIZER INC | 2004-06-03 | — | — | US | claimed |
| WO-2004024729-A1 | DIAZABICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CNS AND OTHER DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-03-25 | — | — | WO | claimed |
| US-7442694-B2 | Diazabicyclic compounds useful in the treatment of CNS and other disorders | PFIZER INC (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1551843-A1 | DIAZABICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CNS AND OTHER DISORDERS | Pfizer Products Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040106603-A1 | Diazabicyclic compounds useful in the treatment of CNS and other disorders | PFIZER INC | 2004-06-03 | — | — | US | disclosed |
| WO-2004024729-A1 | DIAZABICYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CNS AND OTHER DISORDERS | PFIZER PRODUCTS INC. (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106603-A1 | Diazabicyclic compounds useful in the treatment of CNS and other disorders | DBH, CHRNA6, DDT | CHRNB2 10/4885CHRNB4 11/4885CHRNA3 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.